SELLAS Life Sciences (SLS) FCF Margin (2012 - 2022)
SELLAS Life Sciences (SLS) posted quarterly FCF Margin of 715.0% for Q1 2022, down 53484.0% year-over-year from N/an in Q1 2021, and down 177.36% quarter-over-quarter from 257.79% in Q2 2021.
SELLAS Life Sciences (SLS) FCF Margin (2012 - 2022) Analysis & Trends
SELLAS Life Sciences (SLS) has reported FCF Margin for 7 consecutive years, with 715.0% the latest figure, recorded in Q1 2022.
- In Q1 2022, FCF Margin fell 53484.0% year-over-year to 715.0%; the TTM figure through Dec 2022 stood at 2380.9% (down 203852.0% YoY), while the FY2022 annual figure was 2380.9%, down 203852.0% from the prior year.
- FCF Margin retreated to 715.0% in Q1 2022 per SLS's latest filing, from 257.79% in the prior quarter.
- Across five years, FCF Margin topped out at 180.21% in Q4 2020 and bottomed at 715.0% in Q1 2022.
- Historically, FCF Margin has averaged 243.18% across 3 years, with a median of 218.97% in 2021.
- On a YoY basis, FCF Margin climbed as much as 53484 bps in 2022 and fell as far as 53484 bps in 2022.
- SELLAS Life Sciences' FCF Margin stood at 180.21% in 2020, then tumbled by 243 bps to 257.79% in 2021, then slumped by 177 bps to 715.0% in 2022.
- Business Quant data shows SLS's FCF Margin at 715.0% in Q1 2022, 257.79% in Q2 2021, and 180.16% in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,594.17% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 70.82% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.62% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -22.35% |
| 10 | SELLAS Life Sciences | 2.32 Bn | 2.18 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | -715.00% |
| Jun 30, 2021 | -257.79% |
| Mar 31, 2021 | -180.16% |
| Dec 31, 2020 | 180.21% |
| Jun 30, 2015 | -368.21% |
| Mar 31, 2015 | -399.89% |
| Dec 31, 2014 | -336.24% |
| Sep 30, 2014 | -687.28% |
| Jun 30, 2014 | -556.80% |
| Mar 31, 2014 | -371.38% |
| Dec 31, 2013 | -81.53% |
| Sep 30, 2013 | -499.20% |
| Jun 30, 2013 | -305.58% |
| Mar 31, 2013 | -245.33% |
| Dec 31, 2012 | 442.56% |
| Sep 30, 2012 | -355.98% |